An innovative ethosuximide granule formulation designed for pediatric use: Comparative pharmacokinetics, safety, tolerability, and palatability profile versus reference syrup

Ethosuximide, the first‐line therapy for childhood absence epilepsy, is currently formulated as a syrup (Zarontin®, Pfizer) with a bitter taste and high sugar content, poorly adapted to children, and a ketogenic diet. The collaborative European FP7 project KIEKIDS aimed at developing an innovative s...

Descripción completa

Detalles Bibliográficos
Autores principales: Diezi, Léonore, Dao, Kim, Jullien, Vincent, Roussel‐Maupetit, Caroline, Burton, Ingrid, André, Pascal, Bardinet, Carine, Rothuizen, Laura E., Chtioui, Haithem, Manso‐Silvan, Maria A., Guittet, Catherine, Brunner‐Ferber, Françoise, Vandenhende, Francois, Chiron, Catherine, Granier, Luc‐André, Buclin, Thierry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9764106/
https://www.ncbi.nlm.nih.gov/pubmed/36537292
http://dx.doi.org/10.1002/prp2.1032

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9764106/
https://www.ncbi.nlm.nih.gov/pubmed/36537292
http://dx.doi.org/10.1002/prp2.1032

Ejemplares similares